EGFR-Mutated Advanced or Metastatic NSCLC

Disease

Also known as: EGFR-mutated advanced or metastatic NSCLC

Related News

FDA approves once-monthly subcutaneous amivantamab dosing in EGFR-mutated NSCLC

Apr 16, 2026

The FDA approved once-monthly subcutaneous amivantamab with lazertinib for first-line EGFR-mutated advanced NSCLC. PALOMA-2 showed high response rates and no new safety signals.

FDA Approves Monthly Dosing Schedule for Rybrevant Faspro in EGFR-Mutated Lung Cancer

Dec 18, 2025

The FDA approved a once-monthly dosing schedule for Rybrevant Faspro with Lazcluze for first-line treatment of EGFR-mutated advanced NSCLC, reducing clinic visits while maintaining safety and efficacy established with bi-weekly dosing.